NPS Logo


January 5, 2012
NPS Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

December 1, 2011
NPS Pharmaceuticals Completes Submission of New Drug Application for GATTEX(R) (teduglutide) in Adult Short Bowel Syndrome (SBS)

more news


STEPS
NPS has reported positive top line results from STEPS, a Phase 3 clinical trial evaluating GATTEX™ (teduglutide) for reducing parenteral nutrition (PN) dependence in short-bowel syndrome (SBS) patients.  To learn more click here.

REPLACE
NPS has reported positive top line results from REPLACE, a Phase 3 clinical trial evaluating NPSP558 (recombinant full-length human parathyroid hormone 1-84) for the treatment of hypoparathyroidism.  To learn more click here.